Navigation Links
BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
Date:4/17/2008

SAN DIEGO, April 17 /PRNewswire/ -- BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today that it has initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.

"We are encouraged by the enthusiasm expressed by our clinical investigators who view BCI-540 as a potential alternative to today's widely prescribed treatments for depression," noted Carrolee Barlow, M.D., Ph.D., Chief Scientific Officer at BCI. "Current therapies directly impact serotonin levels causing many unpleasant side effects, however we have shown that BCI-540 directly impacts neurogenesis without affecting serotonin levels. We are excited about the potential of this compound to change the way mood disorders are treated."

The twelve-week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80 mg given once or three times daily is effective in the treatment of depression with anxiety versus placebo.

"BCI is utilizing our understanding of the power of neurogenesis coupled with our proprietary neurogenic platform technology to identify a strong portfolio of clinical candidates, such as BCI-540, that we plan to move into the clinic this year," said Jim Schoeneck, CEO at BCI. "Moving BCI-540 into the clinic is an important milestone and we are now actively enrolling patients and anticipate completing enrollment by the end of this year."

About BrainCells Inc.

BrainCells Inc. (BCI) is a San Diego-based drug discovery and development company that is applying its proprietary neurogenesis platform technology to identify and reposition compounds for the treatment of central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of CNS indications. For more information, visit http://www.braincellsinc.com.

Media Contact:

BrainCells Inc.

Kim Richards

Porter Novelli Life Sciences

619-849-5377

krichards@pnlifesciences.com


'/>"/>
SOURCE BrainCells Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
4. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
7. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
8. Metabolex Initiates Phase 1 Trial of MBX-2982
9. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
10. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
Breaking Medicine News(10 mins):